CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 77 filers reported holding CHINOOK THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 2.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $17,824,767 | +58.2% | 463,945 | -4.7% | 0.02% | +50.0% |
| Q1 2023 | $11,264,674 | -12.2% | 486,595 | -0.6% | 0.01% | -23.1% |
| Q4 2022 | $12,830,350 | +40.6% | 489,708 | +5.5% | 0.01% | +44.4% |
| Q3 2022 | $9,128,000 | +3.4% | 464,314 | -8.0% | 0.01% | 0.0% |
| Q2 2022 | $8,829,000 | -33.4% | 504,825 | -37.7% | 0.01% | 0.0% |
| Q1 2022 | $13,266,000 | -3.6% | 810,879 | -3.9% | 0.01% | +12.5% |
| Q4 2021 | $13,762,000 | +28.8% | 843,812 | +0.7% | 0.01% | +33.3% |
| Q3 2021 | $10,688,000 | -9.8% | 837,576 | -0.2% | 0.01% | 0.0% |
| Q2 2021 | $11,852,000 | -9.8% | 839,380 | -0.7% | 0.01% | -14.3% |
| Q1 2021 | $13,139,000 | -1.9% | 845,485 | +0.1% | 0.01% | 0.0% |
| Q4 2020 | $13,397,000 | +29.2% | 844,684 | -80.2% | 0.01% | 0.0% |
| Q3 2020 | $10,366,000 | – | 4,265,980 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $135,241,466 | 29.11% |
| Octagon Capital Advisors LP | 2,551,703 | $66,854,619 | 10.41% |
| Affinity Asset Advisors, LLC | 818,035 | $21,432,517 | 8.40% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $113,853,646 | 7.08% |
| Saturn V Capital Management LP | 423,177 | $6,728,298 | 5.58% |
| Altium Capital Management LP | 385,000 | $10,087,000 | 5.13% |
| Deep Track Capital, LP | 3,000,000 | $78,600,000 | 3.30% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 340,389 | $8,914,788 | 2.75% |
| Vivo Capital, LLC | 872,151 | $22,850 | 2.63% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,985,490 | 2.06% |